Studies have shown that blockade of the CSF1/CSF1R pathway reduces the number of M2 TAMs and decreases PD‐L1 and ARG1 expression; it also reshapes the tumor immune microenvironment and enhances sensitivity to immune checkpoint inhibitor therapy [211, 212]. Here, CSF1 is linked to neoplasm.